Kools FRW - Search Results

1

A mixed method study investigating the key translational competencies acquired during a challenge-based course.

Kools FRW, Fox CM, Prakken BJ, van Rijen HVM. Kools FRW, et al. BMC Med Educ. 2024 Dec 18;24(1):1439. doi: 10.1186/s12909-024-06473-0. BMC Med Educ. 2024. PMID: 39695552 Free PMC article.

2

International online mentorship for translational researchers.

Kools FRW, Fox CM, van Rijen HVM, Prakken BJ. Kools FRW, et al. BMC Med Educ. 2024 Oct 10;24(1):1121. doi: 10.1186/s12909-024-06107-5. BMC Med Educ. 2024. PMID: 39390484 Free PMC article.

3

Practical tips for organizing challenge-based learning in biomedical education.

Kools FRW, van Ravenswaaij H. Kools FRW, et al. MedEdPublish (2016). 2023 Nov 8;13:271. doi: 10.12688/mep.19755.1. eCollection 2023. MedEdPublish (2016). 2023. PMID: 38144873 Free PMC article.

4

One size does not fit all: an exploratory interview study on how translational researchers navigate the current academic reward system.

Kools FRW, Fox CM, Prakken BJ, van Rijen HVM. Kools FRW, et al. Front Med (Lausanne). 2023 May 5;10:1109297. doi: 10.3389/fmed.2023.1109297. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37215726 Free PMC article.

5

Clinician-scientists: how to reverse their declining numbers.

Kools FRW, Prakken B. Kools FRW, et al. Nature. 2022 Jan;601(7893):318. doi: 10.1038/d41586-022-00095-6. Nature. 2022. PMID: 35042993 No abstract available.

6

Publications Are Not the Finish Line: Focusing on Societal Rather Than Publication Impact.

Kools FRW, Mirali S, Holst-Bernal S, Nijhof SL, Cavalli G, Grandner MA. Kools FRW, et al. Front Med (Lausanne). 2018 Nov 12;5:314. doi: 10.3389/fmed.2018.00314. eCollection 2018. Front Med (Lausanne). 2018. PMID: 30483507 Free PMC article. No abstract available.

7

Lysyl oxidase-like 2 is a regulator of angiogenesis through modulation of endothelial-to-mesenchymal transition.

de Jong OG, van der Waals LM, Kools FRW, Verhaar MC, van Balkom BWM. de Jong OG, et al. Among authors: kools frw. J Cell Physiol. 2019 Jul;234(7):10260-10269. doi: 10.1002/jcp.27695. Epub 2018 Nov 1. J Cell Physiol. 2019. PMID: 30387148 Free PMC article.

8

Correction: Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice.

Reeves PM, Abbaslou MA, Kools FRW, Vutipongsatorn K, Tong X, Gavegnano C, Schinazi RF, Poznansky MC. Reeves PM, et al. Among authors: kools frw. Oncotarget. 2018 Jul 13;9(54):30472. doi: 10.18632/oncotarget.25791. eCollection 2018 Jul 13. Oncotarget. 2018. PMID: 30101001 Free PMC article.

9

Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice.

Reeves PM, Abbaslou MA, Kools FRW, Vutipongsatorn K, Tong X, Gavegnano C, Schinazi RF, Poznansky MC. Reeves PM, et al. Among authors: kools frw. Oncotarget. 2017 Oct 4;8(55):94040-94053. doi: 10.18632/oncotarget.21541. eCollection 2017 Nov 7. Oncotarget. 2017. PMID: 29212208 Free PMC article.

10

CXCR4 blockade with AMD3100 enhances Taxol chemotherapy to limit ovarian cancer cell growth.

Reeves PM, Abbaslou MA, Kools FRW, Poznansky MC. Reeves PM, et al. Among authors: kools frw. Anticancer Drugs. 2017 Oct;28(9):935-942. doi: 10.1097/CAD.0000000000000518. Anticancer Drugs. 2017. PMID: 28817386

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10 results

Search Page

Filters